at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre
Company profile
Ticker
SYBX
Exchange
Website
CEO
Aoife Brennan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Mirna Therapeutics, Inc.
SEC CIK
Corporate docs
Subsidiaries
Synlogic Operating Company, Inc. • Synlogic Securities Corporation ...
SYBX stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
21 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
19 Mar 24
8-K
Departure of Directors or Certain Officers
22 Feb 24
8-A12B
Registration of securities on exchange
20 Feb 24
8-K
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process
20 Feb 24
8-K
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
12 Feb 24
8-K
Departure of Directors or Certain Officers
29 Dec 23
8-K
Departure of Directors or Certain Officers
17 Nov 23
8-K
Departure of Directors or Certain Officers
15 Nov 23
Transcripts
SYBX
Earnings call transcript
2022 Q2
11 Aug 22
SYBX
Earnings call transcript
2022 Q1
12 May 22
SYBX
Earnings call transcript
2021 Q4
17 Mar 22
SYBX
Earnings call transcript
2021 Q3
10 Nov 21
SYBX
Earnings call transcript
2021 Q2
12 Aug 21
SYBX
Earnings call transcript
2021 Q1
13 May 21
SYBX
Earnings call transcript
2020 Q4
25 Mar 21
SYBX
Earnings call transcript
2020 Q3
7 Nov 20
SYBX
Earnings call transcript
2020 Q3
5 Nov 20
SYBX
Earnings call transcript
2020 Q2
9 Aug 20
Latest ownership filings
144
Notice of proposed sale of securities
22 Apr 24
SC 13G
Radoff Bradley Louis
18 Apr 24
4
Mary Beth Dooley
4 Apr 24
4
Antoine Awad
4 Apr 24
3
Mary Beth Dooley
21 Mar 24
4
James P Flynn
21 Mar 24
3
James P Flynn
21 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
3
Jacob Ma-Weaver
16 Feb 24
SC 13D
Funicular Funds, LP
16 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.63 mm | 25.63 mm | 25.63 mm | 25.63 mm | 25.63 mm | 25.63 mm |
Cash burn (monthly) | 7.24 mm | (no burn) | 4.21 mm | 5.15 mm | 4.32 mm | 4.87 mm |
Cash used (since last report) | 49.41 mm | n/a | 28.71 mm | 35.15 mm | 29.46 mm | 33.25 mm |
Cash remaining | -23.78 mm | n/a | -3.08 mm | -9.52 mm | -3.83 mm | -7.62 mm |
Runway (months of cash) | -3.3 | n/a | -0.7 | -1.8 | -0.9 | -1.6 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 44 |
Opened positions | 3 |
Closed positions | 9 |
Increased positions | 8 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 13.79 bn |
Total shares | 32.35 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
FMR | 10.14 mm | $4.36 bn |
Orbimed Advisors | 6.03 mm | $2.59 bn |
NEA Management | 4.23 mm | $1.82 bn |
Atlas Venture Associates IX | 2.65 mm | $1.14 bn |
Alyeska Investment | 2.52 mm | $1.08 bn |
Vanguard | 2.24 mm | $964.74 mm |
Ubs Oconnor | 608.23 k | $261.54 mm |
Sofinnova Investments | 574.97 k | $247.24 mm |
Geode Capital Management | 400.01 k | $172.00 mm |
Fiduciary Trust | 335.29 k | $144.18 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Antoine Awad | Common Stock | Sell | Dispose S | No | No | 1.73 | 372 | 643.56 | 33,859 |
2 Apr 24 | Mary Beth Dooley | Common Stock | Sell | Dispose S | No | No | 1.73 | 188 | 325.24 | 15,231 |
19 Mar 24 | James P Flynn | Stock Option Common Stock | Grant | Acquire A | No | No | 1.78 | 4,000 | 7.12 k | 4,000 |
News
HC Wainwright & Co. Upgrades Synlogic to Neutral
20 Mar 24
Synlogic Q4 EPS $(1.71) Misses $(0.97) Estimate, Sales $2.77M Beat $2.73M Estimate
19 Mar 24
Synlogic Adopts Limited Duration Stockholders Rights Plan And Authorized A Dividend Distribution Of One Right For Each Outstanding Share Of Common Stock; Effective Immediately And Has A 1-Year Duration, Expiring On February 20, 2025
20 Feb 24
Why Synlogic (SYBX) Stock Is Down Nearly 50% Today
9 Feb 24
Crude Oil Moves Higher; Newell Brands Issues Weak Outlook
9 Feb 24
Press releases
Synlogic Adopts Limited Duration Stockholders Rights Plan
20 Feb 24
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
8 Feb 24
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
2 Feb 24